Physician profile
Fernando Nussenbaum
NPI 1205274800
$17,710.94
in general payments reported to CMS, 2019-2025
28 companies · $3,360 in 2025
The $3,360 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,737 · 2020: $30.48 · 2021: $37.63 · 2022: $1,707 · 2023: $174 · 2024: $3,664 · 2025: $3,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,880 · Travel and Lodging: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.16 |
| Travel and Lodging | $3,318.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $10,600.76 | 2019-2025 | Real Intelligence, Journey II, Journey |
| Zimmer Biomet Holdings, INC. | $4,724.88 | 2022-2025 | Avenir, Rosa, Mymobility Platform |
| Depuy Synthes Sales INC. | $854.16 | 2022-2025 | Na, Va-Lcp, Tfn-Advance |
| Stryker Corporation | $663.72 | 2024-2025 | Mako, T2 Alpha, Actishield |
| Alon Medical Technology | $141.81 | 2025 | |
| Spine Wave, INC. | $93.85 | 2023 | Spinal Implant |
| Janssen Biotech, INC. | $79.68 | 2025 | Tremfya |
| Lundbeck LLC | $66.09 | 2025 | Vyepti |
| Pfizer INC. | $54.66 | 2020-2025 | |
| Argenx US, INC. | $41.23 | 2024-2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $38.38 | 2025 | |
| Si-Bone, INC. | $36.76 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $35.80 | 2021-2025 | Exparel |
| Vertex Pharmaceuticals Incorporated | $29.56 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $27.64 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $22.59 | 2025 | Radicava |
| Biogen, INC. | $22.54 | 2025 | Tysabri, Vumerity |
| Astrazeneca Pharmaceuticals LP | $21.00 | 2025 | Wainua |
| Eisai INC. | $19.72 | 2025 | |
| Amneal Pharmaceuticals LLC | $19.02 | 2025 | Rytary |
| Spinal Simplicity, LLC | $18.41 | 2025 | Ha Minuteman G3-R |
| Amgen INC. | $17.32 | 2025 | |
| Ermi LLC | $17.12 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.81 | 2025 | Xeomin |
| Alexion Pharmaceuticals, INC. | $14.34 | 2025 | Strensiq |
| Endo USA, INC. | $13.73 | 2025 | Xiaflex |
| Electronic Waveform Lab, INC. | $11.26 | 2020 | |
| Saluda Medical Americas, INC. | $10.10 | 2024 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Nussenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.